Committees & Working Groups
PMC’s member working groups are advancing personalized medicine on behalf of institutions from every sector of the health care ecosystem.
Public Policy Committee
PMC’s Public Policy Committee collaborates to align policy priorities among PMC members and leverage relationships with policymakers to advance legislation and regulations that promote investment in and adoption of personalized medicine.
Science Policy Committee
PMC’s Science Policy Committee collaborates to develop and align medical practices and policies with the evolving base of evidence demonstrating the clinical and economic benefits of personalized medicine.
Six Working Groups
PMC presently maintains six working groups focused on addressing outstanding opportunities and challenges in personalized medicine.
For more information about PMC working groups, please email Vice President for Membership & Development Kayla Brown at kbrown@personalizedmedicinecoalition.org.
PMC’s Artificial Intelligence Working Group will consider the use, regulation and impact of AI/ML on personalized medicine; discuss the potential scope of PMC’s future engagement on AI/ML; and develop policy principles informing PMC’s future advocacy activities.
PMC’s Health Data Working Group convenes members with expertise and interest in information technology, data, real-world evidence, and privacy issues. The group has helped develop PMC principles encouraging institutions to share data in ways that keep patients engaged as fully informed research partners.
PMC’s Inflation Reduction Act (IRA) Working Group convenes to discuss opportunities to impact implementation of the IRA‘s Medicare Drug Price Negotiation Program and to call for technical changes that could improve the prospects for personalized medicine in the context of negotiation activity.
PMC’s Patient Advocacy Organization Working Group provides a forum for the Coalition’s patient advocacy organization members to inform PMC’s policy strategy, align on legislative priorities, and develop shared messages that can empower individual patients to advocate for policies that bring personalized medicine closer to them.
PMC’s Pharmaceutical & Diagnostics Industry Working Group provides a forum for the Coalition’s pharmaceutical and diagnostic industry members to inform PMC’s policy strategy and advocacy activities related to research and development, regulatory oversight, reimbursement, payment reform, and health care quality.
PMC’s Pharmacogenomics (PGx) Working Group convenes members with interest or expertise in issues related to PGx testing. The group guides PMC’s efforts in pharmacogenomics and its related engagements with FDA, clinical guidelines developers, and other stakeholders.
